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Summary
Background Addition of taxanes to preoperative chemotherapy in breast cancer increases the proportion of patients 
who have a pathological complete response (pCR). However, a substantial proportion of patients do not respond, and 
the prognosis is particularly poor for patients with oestrogen-receptor (ER)/progesterone-receptor (PR)/human 
epidermal growth factor receptor 2 (HER2; ERBB2)-negative (triple-negative) disease who do not achieve a pCR. 
Reliable identiﬁ cation of such patients is the ﬁ rst step in determining who might beneﬁ t from alternative treatment 
regimens in clinical trials. We previously identiﬁ ed genes involved in mitosis or ceramide metabolism that inﬂ uenced 
sensitivity to paclitaxel, with an RNA interference (RNAi) screen in three cancer cell lines, including a triple-negative 
breast-cancer cell line. Here, we assess these genes as a predictor of pCR to paclitaxel combination chemotherapy in 
triple-negative breast cancer. 
Methods We derived a paclitaxel response metagene based on mitotic and ceramide genes identiﬁ ed by functional 
genomics studies. We used area under the curve (AUC) analysis and multivariate logistic regression to retrospectively 
assess the metagene in six cohorts of patients with triple-negative breast cancer treated with neoadjuvant chemotherapy; 
two cohorts treated with paclitaxel (n=27, 30) and four treated without paclitaxel (n=88, 28, 48, 39). 
Findings The metagene was associated with pCR in paclitaxel-treated cohorts (AUC 0·79 [95% CI 0·53–0·93], 0·72 
[0·48–0·90]) but not in non-paclitaxel treated cohorts (0·53 [0·31–0·77], 0·59 [0·22–0·82], 0·53 [0·36–0·71], 0·64 
[0·43–0·81]). In multivariate logistic regression, the metagene was associated with pCR (OR 19·92, 2·62–151·57; 
p=0·0039) with paclitaxel-containing chemotherapy.
Interpretation The paclitaxel response metagene shows promise as a paclitaxel-speciﬁ c predictor of pCR in patients 
with triple-negative breast cancer. The metagene is suitable for development into a reverse transcription-PCR assay, 
for which clinically relevant thresholds could be established in randomised clinical trials. These results highlight the 
potential for functional genomics to accelerate development of drug-speciﬁ c predictive biomarkers without the need 
for training clinical trial cohorts.
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Danish Council for Independent Research-Medical Sciences (FSS); Breast Cancer Research Foundation (New York); 
Fondation Luxembourgeoise contre le Cancer; the Fonds National de la Recherche Scientiﬁ que; Brussels Region 
(IRSIB-IP, Life Sciences 2007) and Walloon Region (Biowin-Keymarker); Sally Pearson Breast Cancer Fund; and the 
European Commission.
Introduction
Despite the use of modern cytotoxic agents, the proportion 
of patients who achieve a complete pathological response 
(pCR) to preoperative chemotherapy remains low, at 
15–25% for all breast-cancer histopathological subtypes.1 
Rates of pCR in sporadic oestrogen-receptor (ER)/
progesterone-receptor (PR)/human epidermal growth 
factor receptor 2 (HER2; ERBB2)-negative (triple-negative) 
breast cancer range from 12% for taxane monotherapy to 
45% with combination neoadjuvant chemotherapy 
regimens.2–4 Patients who achieve a pCR after chemotherapy 
have excellent disease-free and overall survival.1 The 
outcome for patients who do not achieve a pCR varies, and 
the prognosis for patients with triple-negative cancers and 
residual disease after preoperative chemotherapy is 
particularly poor.2 Better understanding of breast-cancer 
biology is likely to expand the list of potentially eﬀ ective 
chemotherapeutic agents in the neoadjuvant setting, and 
will help identify tailored chemotherapy schedules for 
distinct patient cohorts based on tumour molecular 
characterisation. If it can be reliably established that 
patients resistant to one type of therapy are sensitive to a 
diﬀ erent agent, then robust predictors of chemotherapy 
response will have an essential role in selecting the 
optimum treatment in the neoadjuvant setting. The 
identiﬁ cation of patients with disease that is resistant to 
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conventional chemotherapy combinations is the ﬁ rst step 
in this process.
Several predictive biomarkers have been discovered 
using associative-learning strategies. Predictive gene-
expression signatures derived from an associative analysis 
approach are susceptible to chance associations which 
lead to overestimation of true clinical accuracy; therefore, 
two separate trial cohorts are required to train and validate 
the predictive signature.5,6 Associative strategies developed 
from genomics signatures that are predictive of drug 
response in cell lines might circumvent the need for 
training and validation of trial cohorts.7 Quantifying 
distinct biological processes within gene-expression 
datasets, instead of a gene-by-gene based associative 
analysis, may further avoid these problems and accelerate 
biomarker development.8 However, potentially relevant 
biological processes or functional modules must be 
identiﬁ ed in advance for such an analysis to be possible. 
RNA interference (RNAi) functional screening may be an 
applicable method to identify biological processes relevant 
to drug response in cancer medicine. To test this hypothesis, 
we revisited results of our previous study9 of an RNAi drug-
resistance screen across three cancer cell lines, including a 
triple-negative breast-cancer cell line, MDA-MB-231. In 
this screen, we identiﬁ ed two distinct gene sets regulating 
sensitivity to paclitaxel.9 The ﬁ rst set of genes is involved in 
mitosis and the mitotic spindle assembly checkpoint 
(SAC), and the second set is involved in metabolism of the 
proapoptotic lipid, ceramide. The involvement of both of 
these gene sets is consistent with the current biological 
understanding of the mechanism of action of paclitaxel. 
An activated SAC orchestrates a paclitaxel-induced mitotic 
arrest, and in our RNAi screen, silencing several genes 
implicated in SAC control impaired the accumulation of 
cells in mitosis and subsequent cell death in response to 
paclitaxel. Identiﬁ cation of ceramide pathway genes as 
regulators of paclitaxel sensitivity9 is consistent with 
published evidence that overexpression of glucosylceramide 
synthase (UGCG) promotes resistance to paclitaxel and 
repression promotes paclitaxel sensitivity.10–12 
We created a metagene using established methodology8,13 
to quantify the activity of these two biological pathways 
identiﬁ ed by our RNAi screen, and tested its paclitaxel-
predictive value in patients with triple-negative breast 
cancer who were treated in clinical trials with either a 
paclitaxel-containing combination regimen, T-FAC 
(paclitaxel followed by ﬂ uorouracil, doxorubicin, and 
cyclophosphamide) or by regimens without paclitaxel.
Methods
Patients and procedures
Gene-expression and treatment-response data were 
retrieved from six cohorts in ﬁ ve neoadjuvant clinical trials, 
referred to in this study as MDA1, MDA/MAQC-II, TOP, 
EORTCFEC, EORTCTET, and DFCI. In all trials, pCR was 
determined at the time of surgery (no evidence of residual 
invasive cancer in the breast or lymph nodes at time of 
MDA1 MDA/
MAQC-II
TOP DFCI EORTC10944
FEC group TET group
Microarray platform U133A U133A U133 Plus 2.0 U133 Plus 2.0 X3P X3P
Treatment T-FAC T-FAC Epirubicin Cisplatin FEC TET
Number of patients 133 100 120 28 102 58 
Median age (years; 
range)
51 
(28–79)
50 
(26–73)
47 
(27–68)
50 
(29–69)
49 
(26–70)
49 
(34–70)
Histology; n (%)
IDC 130 (98) 93 (93) 112 (93) 28 (100) 52 (51) 56 (97)
ILC 1 (1) 7 (7) 1 (1) 0 (0) 4 (4) 2 (3)
Other 2 (1) 0 (0) 7 (6) 0 (0) 7 (7) 0 (0)
Unknown 0 (0) 0 (0) 0 (0) 0 (0) 39 (38) 0 (0)
Stage; n (%)
T1 13 (10) 10 (10) 17 (14) 1 (4) 2 (2) 1 (2)
T2 70 (52·5) 62 (62) 83 (69) 22 (79) 63 (62) 37 (64)
T3 22 (16·5) 13 (13) 5 (4) 4 (14) 34 (33) 20 (34)
T4 28 (21) 15 (15) 15 (13) 0 (0) 0 (0) 0 (0)
Unknown 0 (0) 0 (0) 0 (0) 1 (4) 3 (3) 0 (0)
Nodes; n (%)
SLN positive ND ND ND 13 (46) ND ND
N0 40 (30) 27 (27) 55 (46) 15 (54) 37 (36) 22 (38)
N1 62 (47) 47 (47) 60 (50) ND 55 (54) 31 (53)
N2 14 (11) 13 (13) 3 (2) ND 7 (7) 5 (9)
N3 17 (13) 13 (13) 2 (2) ND 0 (0) 0 (0)
Unknown 0 (0) 0 (0) 0 (0) 0 (0) 3 (3) 0 (0)
Grade; n (%)
1 2 (1) 11 (11) 2 (2) 0 (0) 2 (2) 0 (0)
2 54 (41) 42 (42) 20 (17) 0 (0) 21 (21) 16 (28)
3 77 (58) 47 (47) 92 (77) 28 (100) 31 (30) 37 (64)
Unknown 0 (0) 0 (0) 6 (5) 0 (0) 48 (47) 5 (9)
Oestrogen receptor status; n (%)
Positive 82 (62) 61 (61) 1 (1) 0 (0) 37 (36) 0 (0)
Negative 51 (38) 39 (39) 119 (99) 28 (100) 65 (64) 58 (100)
Progesterone receptor status; n (%)
Positive 75 (56) 51 (51) 1 (1) 0 (0) 25 (25) 0 (0)
Negative 55 (41) 49 (49) 75 (62) 28 (100) 75 (74) 58 (100)
Unknown 3 (2) 0 (0) 44 (37) 0 (0) 2 (2) 0 (0)
HER2 status; n (%)
Ampliﬁ ed 33 (25) 7 (7) 32 (27) 0 (0) 26 (25)* 19 (33)*
Not ampliﬁ ed 99 (74) 93 (93) 61 (51) 28 (100) 76 (75)* 39 (67)*
Unknown 1 (1) 0 (0) 27 (23) 0 (0) 0 (0)* 0 (0)*
Total triple-negative; 
n (%)
27 (20) 30 (30) 88 (73)** 28 (100) 48 (47) 39 (67)
Response; n (%)
pCR 34 (26) 15 (15) 17 (14) 5 (18) 39 (38) 26 (45)
No pCR 99 (74) 85 (85) 101 (84) 21 (75) 63 (62) 32 (55)
Non-evaluable 0 (0) 0 (0) 2 (2) 2 (7) 0 (0) 0 (0)
T stage was measured before treatment. Nodal status was conﬁ rmed at surgery for MDA1, MDA/MAQC-II, 
TOP, and EORTC. Nodal status for DFCI was assessed before treatment with SLN biopsy. T-FAC=paclitaxel, 
ﬂ uorouracil, doxorubicin, and cylclophosphamide. FEC=ﬂ uorouracil, epirubicin, and cyclophosphamide. 
TET=docetaxel followed by epirubicin and docetaxel. IDC=invasive ductal carcinoma. ILC=invasive lobular 
carcinoma. SLN=sentinel lymph node. ND=not determined. pCR=pathological complete response. *Receptor 
status inferred by gene expression. **Triple-negative breast cancer subtype inferred by expression when 
insuﬃ  cient data by immunohistochemistry/FISH.
Table 1: Clinical and histopathological characteristics of the cohorts analysed
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surgery). Two clinical trial cohorts were treated with 
paclitaxel-containing regimens (T-FAC): the MDA1 cohort14 
and the MDA/MAQC-II cohort (GEO accession number 
GSE16716). Patients in the TOP cohort (GSE16446) were 
treated with neoadjuvant epirubicin. The gene expression 
substudy of the EORTC 10994 trial7,8 randomised patients 
to FEC (ﬂ uorouracil, epirubicin, and cyclophosphamide) 
or TET (docetaxel followed by epirubicin and docetaxel), 
corresponding to the EORTCFEC (GSE6861) and EORTCTET 
(GSE4779) subgroups, respectively. In the DFCI cohort 
(GSE18864), triple-negative patients were treated with 
neoadjuvant cisplatin.15 Patient characteristics for all 
cohorts are summarised in table 1, and characteristics for 
the subset of patients with triple-negative disease are 
shown in the webappendix p 1. We referred to microarray-
based expression subtyping if we were unable to fully 
classify tumours by histology. All clinical trials 
and translational parameters were approved by the 
ethics committee and institutional review boards 
of the participating institutions. Further cohort-speciﬁ c 
information is detailed in the webappendix pp 10–12.
Validated datasets from our previously published RNAi 
screen were used for the derivation of the paclitaxel 
response metagene (webappendix pp 10–12).9 The RNAi 
screen focused on kinases and ceramide-pathway genes. 
In the kinase screen, we identiﬁ ed ten mitosis-associated 
genes that inﬂ uenced sensitivity to paclitaxel in three 
diﬀ erent cell lines. In addition, we identiﬁ ed three genes 
from the ceramide pathway (COL4A3BP, GBA1, GBA3)
that together with the published gene UGCG,10–12 encode 
proximal regulators of ceramide metabolism and inﬂ uence 
paclitaxel sensitivity. Of these 14 genes (ﬁ gure 1), six 
mitotic genes and three ceramide genes could be assayed 
on the Aﬀ ymetrix HGU133A platform, and these were 
combined into the mitotic and the ceramide gene sets. 
The number of genes within each gene set was further 
reduced to the mitotic module (four genes) and the 
ceramide module (two genes) by only including genes that 
were signiﬁ cantly correlated with each other across four 
independent breast cancer datasets.16–19 The expression of 
the genes within each module was compressed by taking 
the mean. Since the two modules were expected to 
predict sensitivity in the opposite direction 
(high mitotic expression=sensitivity, high ceramide 
expression=resistance), the paclitaxel response metagene 
was deﬁ ned as the mitotic module minus the ceramide 
module. As a comparison, 10 000 random combinations of 
nine-gene sets were subjected to the same correlative 
approach, across four clinical datasets, and the mean 
expression of signiﬁ cantly correlated genes were tested for 
their ability to predict pCR in T-FAC-treated cohorts. We 
also did a literature search and found 24 genes reported as 
aﬀ ecting taxane sensitivity when either overexpressed or 
repressed (webappendix p 6). These genes were subjected 
to the same correlation analysis as the paclitaxel response 
metagene, and the reported direction of expression 
relating to paclitaxel sensitivity was included as weights 
(minus 1 if the gene induced sensitivity when repressed, 
1 if the gene induced sensitivity when overexpressed). The 
genomic grade index and the stroma signatures were 
calculated as described previously.8,20
Statistical analysis
A binomial test was used to test for enrichment in genes 
that predicted response to treatment with paclitaxel-
containing neoadjuvant chemotherapy, among the 
genes that substantially aﬀ ected paclitaxel sensitivity 
across three cell lines. The signiﬁ cance of association 
between module or metagene scores and pCR was 
estimated with the one-sided Wilcoxon signed-rank test 
and plotted with receiver operating characteristics 
curves. We used a one-sided Wilcoxon test because we 
had a prior expectation about the direction of association, 
based on the RNAi screening results.9 The eﬀ ect size 
was estimated with AUC and logistic regression. Since 
the MDA1 and MDA/MAQC-II trials were done by the 
same investigators, at the same site, with identical gene-
expression platforms, we combined the two T-FAC 
Figure 1: Process to derive the paclitaxel response metagene 
(A) Flow chart describing the derivation of the gene modules and the paclitaxel response metagene. UGCG was 
identiﬁ ed from the literature as a gene in the same pathway that promotes paclitaxel sensitivity when repressed. 
(B) Proximal regulators of the proapoptotic lipid, ceramide, that alter paclitaxel sensitivity through conversion to 
sphingomyelin (via COL4A3BP ceramide transporter) or glucosylceramide (UGCG glucosylceramide synthase) and 
conversion of glucosylceramide to ceramide (GBA1 and GBA3 beta-glucosidase). Genes for which repression 
promotes paclitaxel sensitivity are shown in green and for which repression promotes paclitaxel resistance are 
shown in red. RNAi=RNA interference.
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See Online for webappendix
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treated cohorts to increase statistical power for univariate 
and multivariate logistic regression analysis. Univariate 
and multivariate logistic regression was done using 
iteratively reweighted least squares. All covariates were 
converted to binary, using the median as a threshold to 
determine paclitaxel response metagene status and Ki67 
status. Analyses compared stage T3 and T4 versus T1 
and T2; grade 3 versus grade 1 and 2; and N0 versus 
N1+. A p value of 0·05 or lower was considered 
signiﬁ cant for all statistical tests. All statistical analyses 
were done in R version 2.9.2 using the software packages 
aﬀ y, geneﬁ lter, beeswarm, gdata, ROC, hgu133a.db, 
u133x3p.db, squash, boot, rmeta, and survplot (web-
appendix p 11). 
Role of the funding source
The funding sources and sponsors of the trials had no 
role in the design of the study; collection, analysis, or 
interpretation of the data; or writing of this report. All 
authors had access to the raw data. The corresponding 
author had full access to all data and had the ﬁ nal 
responsibility to submit for publication.
Results
To develop an analytical framework based on 
experimentally established functional links instead of 
associative correlations, we revisited our previously 
published functional genomic RNAi screen that identiﬁ ed 
genes which either promote resistance or sensitivity to 
paclitaxel.9  Based on this screen and previously published 
data, we identiﬁ ed two gene modules of tightly correlated 
genes: a four-gene mitotic module where higher expression 
predicted sensitivity, and a two-gene ceramide module 
where higher expression predicted resistance. We then 
used the mean expression of the genes within each 
module as a single predictive value; an approach previously 
shown to improve reliability across many tumour 
samples.8,13 Finally, we combined the mitotic and ceramide 
modules into a single functionally derived paclitaxel-
response metagene by subtracting the mean expression of 
the genes in the ceramide module from the mean 
expression of the genes in the mitotic module (ﬁ gure 1). 
Therefore, this summary measure reﬂ ects the diﬀ erence 
in the mean expression of the two modules and is 
predicted to correlate with paclitaxel sensitivity.
In the T-FAC treated triple-negative cohorts, the 
paclitaxel response metagene was highly predictive of 
pCR, with an AUC of 0·79 in MDA1 (p=0·0053; 95% CI 
0·53–0·93; n=27), an AUC of 0·72 in MDA/MAQC 
(p=0·031; 0·48–0·90; n=30), and an AUC of 0·74 when 
the two cohorts were combined (p=0·0013; 0·58–0·86; 
n=57; table 2, ﬁ gure 2 A and B, webappendix p 2). 
Consistent with these data, the paclitaxel response 
metagene was also predictive of response across all 
patients in each cohort: for MDA1, AUC was 0·79 
(p<0·0001; 0·69–0·87; n=133); for MDA/MAQC-II, AUC 
was 0·76 (p=0·00061; 0·61–0·87; n=100); and for the 
combined cohort, AUC was 0·77 (p<10–⁸; 0·69–0·84; 
n=233; data not shown).
Measurements of gene expression in the cohorts treated 
with neoadjuvant paclitaxel were consistent with in-vitro 
functional observations; repression of genes in the mitotic 
module was associated with resistance to T-FAC therapy, 
and repression of genes in the ceramide module was 
associated with sensitivity to T-FAC. Moreover, genes 
whose suppression increased paclitaxel resistance across 
all three cancer cell lines of diﬀ erent tissue origin were 
enriched in a list of genes that are diﬀ erentially expressed 
in patients who were sensitive or resistant to paclitaxel 
(a binomial test addressing the probability that four of six 
Mitotic module Ceramide module Paclitaxel response metagene Paclitaxel response metagene 
including all module genes
Literature-based metagene
All patients
MDA1 0·73; 0·63–0·82; <0·0001 0·74; 0·62–0·83; <0·0001 0·79 ;0·69–0·87; <0·0001 0·79; 0·68–0·85; <0·0001 0·52; 0·39–0·62; 0·39
MDA/MAQC-II 0·71; 0·52–0·83; 0·0059* 0·73; 0·58–0·85; 0·0023*† 0·76; 0·61–0·87; 0·00061* 0·75; 0·58–0·86; 0·00094* 0·56; 0·35–0·72; 0·77†
TOP 0·49; 0·34–0·65; 0·57 0·50; 0·33–0·69; 0·51† 0·50; 0·34–0·66; 0·52 0·50; 0·36–0·65; 0·49 0·56; 0·41–0·71; 0·80†
EORTCFEC 0·57; 0·45–0·67; 0·11 0·59; 0·48–0·71; 0·061† 0·62; 0·49–0·72; 0·025* 0·62; 0·51–0·72; 0·023* 0·55; 0·43–0·66; 0·81†
EORTCTET 0·53; 0·37–0·68; 0·64 0·54; 0·39–0·69; 0·71† 0·53; 0·38–0·67; 0·65 0·52; 0·37–0·70; 0·61† 0·55; 0·40–0·70; 0·76†
Triple-negative
MDA1 0·70; 0·45–0·87; 0·038* 0·65; 0·41–0·86; 0·093† 0·79; 0·53–0·93; 0·0053* 0·74; 0·51–0·9; 0·017* 0·55; 0·29–0·79; 0·33
MDA/MAQC-II 0·63; 0·36–0·85; 0·14 0·67; 0·38–0·86; 0·075† 0·72; 0·48–0·9; 0·031* 0·71; 0·43–0·88; 0·035* 0·58; 0·31–0·78; 0·75†
TOP 0·50; 0·33–0·72; 0·51 0·55; 0·4–0·74; 0·31† 0·53; 0·31–0·77; 0·38 0·52; 0·3–0·71; 0·42 0·64; 0·38–0·83; 0·91†
EORTCFEC 0·54; 0·36–0·72; 0·3 0·50; 0·33–0·68; 0·52† 0·53; 0·36–0·71; 0·35 0·54; 0·36–0·69; 0·33 0·59; 0·41–0·74; 0·87†
EORTCTET 0·63; 0·44–0·80; 0·92† 0·64; 0·44–0·79; 0·93 0·64; 0·43–0·81; 0·93† 0·61; 0·40–0·78; 0·89† 0·52; 0·31–0·70; 0·59†
DFCI 0·57; 0·04–0·87; 0·33 0·56; 0·28–0·89; 0·35† 0·59; 0·22–0·82; 0·28 0·56; 0·20–0·94; 0·35 0·70; 0·0–0·98; 0·92†
Data are AUC; 95% CI; p value. Histopathological subtypes were based on pathology review by ER/PR/HER2 immunohistochemistry or HER2 FISH, supplemented by expression if histopathological data were 
unavailable. AUC=area under the curve. FEC=ﬂ uorouracil, epirubicin, and cyclophosphamide. TET=docetaxel followed by epirubicin and docetaxel. ER=oestrogen receptor. PR=progesterone receptor. *Signiﬁ cant 
association between module or metagene and treatment response. †These values predict resistance to paclitaxel, all others predict sensitivity.
Table 2: Association between gene sets and treatment response for all patients and for triple-negative patients for each cohort
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mitotic genes from the RNAi screen were signiﬁ cantly 
predictive of pCR in the MDA1 cohort when compared 
with the background probability of 3802/26 138 that a gene 
in the MDA1 cohort was signiﬁ cantly predictive of pCR 
[OR 11·40, 95% CI 2·088–62·29; p=0·0052] and that four 
of six mitotic genes from the RNAi screen were signiﬁ cantly 
predictive of pCR in the MDA/MAQC-II cohort compared 
with the background probability of 1986/26138 that a gene 
in the MDA1 cohort was signiﬁ cantly predictive of pCR 
[OR 23·55, 95% CI 4·31–128·69; p=0·00044], and that four 
of six mitotic genes from the RNAi screen were signiﬁ cantly 
predictive of pCR in both the MDA1 and the MDA/MAQC-
II cohorts compared with the background probability of 
1063/26138 that a gene in both cohorts were signiﬁ cantly 
predictive of pCR [OR 45·61, 95% CI 8·34–249·30; 
p=0·000039). These data suggest that the concordance of 
the functional genomic and clinical trial genomics datasets 
is unlikely to result from a chance association.
For multivariate analysis, we combined the two T-FAC-
treated MDA1 and MDA/MAQC-II cohorts to increase 
statistical power. We found that the paclitaxel response 
metagene was the covariate most signiﬁ cantly associated 
with pCR (p=0·0039; odds ratio 19·92; 95% CI 
2·62–151·57) in T-FAC-treated patients with triple-negative 
breast cancer, more than nodal status, T stage, tumour 
grade, and Ki67 (table 3). The paclitaxel response metagene 
also did better than the genomic grade index and the 
stroma signature in both univariate and multivariate 
analysis of the combined T-FAC clinical trials, when all 
patients were considered and in the triple-negative cohorts 
(table 4).8,20 These data support the conclusion that the 
paclitaxel response metagene derived from an RNAi 
screen has predictive power in two paclitaxel clinical trial 
cohorts that had no role in the discovery of the genes 
included in the metagene. The response metagene was 
not signiﬁ cantly associated with recurrence-free survival 
in two untreated triple-negative breast cancer cohorts, 
indicating the predictive rather than prognostic power of 
the metagene (webappendix p 4).16,18 
To further validate the functional importance of the 
genes contained within the metagene and limit the 
possibility that the correlation step would artiﬁ cially enrich 
for genes predictive of pCR, we tested the ability to predict 
for pCR of 10 000 random nine-gene sets subjected to the 
same correlative approach. None of the 10 000 combinations 
predicted for pCR better than the paclitaxel response 
metagene (p<0·0001). We addressed the relevance of the 
RNAi screening process to select genes for inclusion in the 
metagene by performing the same analysis with 24 genes 
reported to be associated with paclitaxel or docetaxel 
resistance. The literature metagene did not show any 
predictive value in the MDA1 or MDA/MAQC-II cohorts. 
In a further analysis, we eliminated the correlation step 
from the derivation of the paclitaxel response metagene. 
Although the nine-gene set (ﬁ gure 1) selected before the 
expression correlation step was still predictive of pCR with 
T-FAC, this gene set did not do as well as the paclitaxel 
response metagene. These results suggest that unbiased 
selection of correlated genes with consistent phenotypes 
across an RNAi screen improves the performance of the 
predictive metagene (table 2). 
To assess the paclitaxel speciﬁ city of the paclitaxel 
response metagene, we assessed its predictive power in 
four cohorts that did not receive paclitaxel (table 1, 
webappendix p 5): the EORTC 10994 FEC trial cohort, 
EORTC 10994 TET trial cohort, the TOP epirubicin trial 
cohort, and the triple-negative DFCI cisplatin-treated 
cohort. The paclitaxel response metagene did not predict 
response in the triple-negative subtype (p>0·05, 
ﬁ gure 2 C–F). Notably, the paclitaxel response metagene 
did not predict a signiﬁ cant response to the TET 
regimen. The triple-negative tumours analysed were 
somewhat homogeneous (reﬂ ecting the neoadjuvant 
setting of these trials), with similar nodal status, T stage, 
and were higher grade tumours (webappendix p 5), 
indicating that tumour heterogeneity is unlikely to 
account for this result.
Figure 2: Receiver operating characteristic (ROC) curves for the gene modules and the paclitaxel 
response metagene
ROC curve in triple-negative patients in the T-FAC-treated cohorts MDA1 (A) and MDA/MAQC-II (B), the 
epirubicin-treated TOP cohort (C), the FEC-treated EORTC cohort (D), the TET-treated EORTC cohort (E), 
and in the cisplatin-treated DFCI cohort (F). AUC=area under the curve. FEC=ﬂ uorouracil, epirubicin, and 
cyclophosphamide. TET=docetaxel followed by epirubicin and docetaxel. *These values predict paclitaxel 
resistance; all others predict sensitivity.
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Using a meta-analysis, we combined the odds ratios of 
the paclitaxel response metagene to pCR in the two 
paclitaxel-treated cohorts and in the four non-paclitaxel 
treated cohorts. We found that the summary odds ratio of 
the paclitaxel treated cohorts was 5·65 (95% CI 1·67–19·11; 
p=0·0053), whereas the summary odds ratio of the 
non-paclitaxel treated cohorts was 0·87 (95% CI 
0·44 to 1·67; p=0·67), consistent with improved predictive 
power of the paclitaxel response metagene in paclitaxel 
treated cohorts (ﬁ gure 3). 
Finally, we combined paclitaxel-treated with non-
paclitaxel-treated triple-negative cohorts and did logistic-
regression analysis using a mixed eﬀ ects model, 
considering paclitaxel treatment, binary metagene status, 
and their interaction. We observed a signiﬁ cant 
interaction term between paclitaxel treatment and binary 
metagene status (OR 5·9, 95% CI 1·61–23·18; p=0·0089), 
indicating that the paclitaxel response metagene has 
paclitaxel-speciﬁ c predictive power.
Discussion
This study supports the use of high-throughput RNAi 
functional genomics screening to accelerate discovery of 
predictive biomarkers in cancer medicine. By ﬁ ltering for 
common paclitaxel resistance pathways through RNAi 
screening across three cell lines of diﬀ erent tumour origin, 
and selecting genes which correlate across independent 
cohorts, we derived a paclitaxel response metagene that is 
predictive of T-FAC response in two clinical trial datasets, 
but not in cohorts treated without paclitaxel. Our results 
show the usefulness of this approach to identify drug-
speciﬁ c response predictors. Data reported here support a 
model whereby expression of genes that regulate mitotic 
arrest and chromosomal stability, mediated through 
spindle assembly checkpoint signalling, and genes that 
inﬂ uence ceramide conversion to sphingomyelin or 
glucosylceramide, are associated with altered response to 
T-FAC therapy in vivo (ﬁ gure 4).9,21 
Since the metagene was derived from an RNAi screen in 
a triple-negative breast-cancer cell line, we investigated the 
power of the metagene to predict response to paclitaxel in 
clinical trials that include patients with this histological 
subtype. The patient demographics in the four non-
paclitaxel trials included in this study are typical of the 
neoadjuvant setting and similar to MDA1 and MDA/MAQC-
II, with a bias towards node positive, higher grade (G2–G3) 
and larger tumours (T2 and above), indicating that tumour 
heterogeneity across the trial cohorts is unlikely to 
contribute to the observed results. However, although the 
paclitaxel response metagene performs better than 
the genomic grade index and the stromal signature in 
multivariate analysis, both of which have predictive value 
in patients treated with T-FAC,8,20 the AUCs reported in the 
MDA1 cohort result in false negatives and denial of active 
therapy in two of 13 (15%) of the responding patients, to 
spare suboptimal treatment in ten of 14 patients with 
resistant disease. A  false negative proportion of one in 
13 (8%) would be possible by sacriﬁ cing speciﬁ city, 
resulting in the sparing of suboptimal therapy in seven of 
14 patients with resistant disease. A false negative 
proportion of 8% would compare with the false negative 
proportion of ER analysis in breast cancer (Sotiriou C, 
unpublished data). We plan to assess whether the 
Univariate analysis Multivariate analysis
All patients
Oestrogen receptor 0·084; 0·04–0·19; <0·0001* 0·18; 0·07–0·47; 0·00039*
HER2 3·84; 1·84–8·01; 0·00037* 2·35; 1·01–5·47; 0·048*
T stage 1·07; 0·55–2·08; 0·84 0·67; 0·29–1·52; 0·34
Ki67 3·60; 1·79–7·23; 0·00032* 1·17; 0·45–3·07; 0·75
Grade 6·24; 2·77–14·04; <0·0001* 1·99; 0·73–5·44; 0·18
Node 2·42; 1·07–5·48; 0·034* 1·98; 0·77–5·06; 0·15
Metagene 7·28; 3·23–16·41; <0·0001* 1·79; 0·56–5·70; 0·32
Triple-negative
T stage 0·79; 0·26–2·44; 0·68 0·39; 0·09–1·60; 0·19
Ki67 0·79; 0·27–2·29; 0·66 0·10; 0·01–0·80; 0·030*
Grade 3·46; 0·67–17·83; 0·14 6·59; 0·76–57·36; 0·088
Node 3·46; 0·67–17·83; 0·14 9·62; 1·02–90·28; 0·048*
Metagene 4·51; 1·41–14·43; 0·011* 19·92; 2·62–151·57; 0·0039*
Data are odds ratio; 95% CI; p value. All covariates are binary. The binary metagene and binary Ki67 is deﬁ ned as the 
upper vs lower 50th percentile. T stage is T3–4 vs T1–2. Grade is 3 vs 1 and 2. Node is N+ versus N0. *Signiﬁ cant values.
Table 3: Univariate and multivariate analysis for response to treatment (combined analysis)
Univariate analysis Multivariate analysis
All patients
Stroma metagene 0·45; 0·23–0·86; 0·016* 0·55; 0·27–1·11; 0·095
Genomic grade index 4·11; 1·98–8·54; 0·00015* 1·59; 0·66–3·80; 0·30
Paclitaxel response metagene 7·28; 3·23–16·41; <0·0001* 5·37; 2·12–13·64; 0·00040*
Triple-negative
Stroma metagene 0·28; 0·09–0·85; 0·025* 0·27; 0·07–1·03; 0·055
Genomic grade index 2·35; 0·65–8·52; 0·19 0·41; 0·06–2·68; 0·35
Paclitaxel response metagene 4·51; 1·41–14·43; 0·011* 5·47; 1·21–24·76; 0·027*
Data are odds ratio; 95% CI; p value. *Signiﬁ cant values.
Table 4: Performance of the paclitaxel response metagene compared with published gene-expression 
signatures in univariate and multivariate logistic regression (combined analysis)
Figure 3: Odds ratio for pathological complete response in patients with 
high paclitaxel response metagene score, compared with a low score 
FEC=ﬂ uorouracil, epirubicin, and cyclophosphamide. TET=docetaxel followed by 
epirubicin and docetaxel.
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performance of the paclitaxel response metagene approach 
might be improved through gene selection from genome-
wide RNAi screening approaches targeting more than 
21 000 genes across multiple cell lines, by contrast with the 
829 genes assessed in this study.
Sources of random and systematic error should be 
considered when interpreting these data. Notably, the 
triple-negative breast-cancer cohorts are likely to be 
molecularly heterogeneous. Although no patients enrolled 
in the T-FAC trials were known to have germline BRCA 
mutations, the same DNA repair-pathway mechanisms 
may be disrupted in sporadic breast cancers that have also 
been implicated in taxane resistance in vitro.22,23 Also, it 
should be noted that the T-FAC clinical trial datasets were 
acquired from ﬁ ne needle aspirations whereas the non-
paclitaxel datasets were acquired from core biopsies. RNA 
yield and expression proﬁ ling are similar using both 
techniques,24 but we cannot exclude the possibility that the 
enrichment of stromal elements in the core biopsy datasets 
contribute to the lack of predictive power of the paclitaxel 
response metagene. There is heterogeneity between the 
clinical studies including the timing and measurement of 
pCR by diﬀ erent pathological centres. The ﬁ ve trials ex-
amined here varied in chemotherapy exposure from 12 to 
24 weeks, and two trials used monotherapy schedules that 
might aﬀ ect the proportion of patients achieving a pCR. 
A metagene derived from reports of genes implicated 
in taxane resistance did not show T-FAC predictive power. 
Furthermore, none of 10 000 random nine-gene sets 
performed better than the metagene. While these results 
support the RNAi approach to biomarker discovery and 
argue against the role of chance in these ﬁ ndings, the 
modest cohort sizes and the heterogeneity of the non-
paclitaxel trials require replication in larger prospective 
studies to conﬁ rm the relevance of this method with a 
clinically applicable gene-expression assay. Experience 
with the Oncotype DX assay has shown that RNA-based 
expression measurements (real-time PCR) from paraﬃ  n-
ﬁ xed tumour material can inform clinical decision 
making. A similar assay to assess the expression of the 
paclitaxel response metagene could be developed that, 
we estimate, would cost less than €30 per patient. With 
this assay, exact thresholds of mitotic and ceramide 
module expression should be deﬁ ned retrospectively 
with tumours from the T-FAC trial before testing the 
deﬁ ned threshold in a prospective trial. A randomised 
clinical trial comparing a paclitaxel with a non-paclitaxel 
regimen will be required to formally support the 
paclitaxel-speciﬁ city of the metagene and the relevance of 
RNAi to the biomarker discovery process. The usefulness 
of this approach in routine clinical practice should then 
be assessed, since patients enrolled in clinical trials may 
not accurately reﬂ ect the demographics and clinical stage 
of patients diagnosed with primary breast cancer. 
Notably, the paclitaxel response metagene was not 
predictive of pCR in the EORTCTET cohort (docetaxel then 
epirubicin and docetaxel), which may be explained by the 
non-overlapping pathways of drug resistance to the two 
taxanes. The metagene was derived from a screen to 
identify mediators of paclitaxel not docetaxel resistance 
across three cell lines, and preclinical data has shown 
that docetaxel binds to β-tubulin with greater aﬃ  nity 
than paclitaxel and has increased interphase (G1/S/G2) 
cell-cycle activity, mediating cell death through the 
induction of BCL2 phosphorylation.25,26 Finally, 19–31% of 
patients respond to paclitaxel having progressed on or 
after docetaxel,27,28 supporting the divergent drug-
resistance mechanisms of these two taxanes.
We cannot be certain that the paclitaxel response 
metagene is paclitaxel speciﬁ c, despite the test for 
interaction, since silencing of COL4A3BP and UGCG has 
been shown to promote doxorubicin sensitisation.9,29 
Consistent with this hypothesis, we note that the paclitaxel 
response metagene is weakly predictive of pCR in the 
EORTCFEC dataset across all patients (AUC 0·62; 95% CI 
0·49–0·72; p=0·025). The ceramide module is likely the 
main contributor, since COL4A3BP expression alone 
predicts for pCR in all patients (0·59; 0·48–0·71; p=0·061); 
this would support the role of the ceramide pathway in 
the regulation of multidrug sensitivity in vivo.
In summary, we used in-vitro functional genomics 
analyses to guide the development of a metagene to 
predict paclitaxel response in patients with breast cancer. 
Although we cannot conclude that our approach is better 
than associative predictive strategies, the latter strategy 
Figure 4: Model for the role of the metagene in paclitaxel response
Paclitaxel stabilises microtubules (green) and causes mitotic arrest, due to spindle assembly checkpoint signalling 
(red) generated by unattached kinetochores (yellow). BUB1B, TTK, and AURKB all have roles in checkpoint signalling, 
which maintains the activity of CDC2 to keep cells arrested in mitosis. AURKB may maintain checkpoint activation 
through detachment of syntelic attachments (purple rings and magniﬁ ed section) which may be promoted during 
paclitaxel exposure. Following a mitotic arrest, sensitive tumour cells undergo apoptosis. The mechanisms for this are 
currently unclear. Ceramide is a proapoptotic lipid that may contribute to paclitaxel-induced cell death following a 
mitotic arrest. Decreased levels of the mitotic module may attenuate a mitotic arrest, and consequently, cell death. 
Conversely, decreased levels of the ceramide transporter, COL4A3BP (CERT), and glucosylceramide synthase, UGCG, 
may lead to an increase in the ceramide pool and potentiate paclitaxel-induced cytotoxicity.
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requires training of two large cohorts and validation of 
such signatures. The functional genomics approach used 
in this study could be an eﬃ  cient method to accelerate 
biomarker development for experimental therapies in 
single-cohort early phase clinical trials, where strat-
iﬁ cation of response according to tumour expression of a 
functional metagene could be considered.
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